Stabilizes the bilayer
C15:0 is incorporated into membrane phospholipids. With no double bonds to oxidize, it resists lipid peroxidation and helps the membrane keep its structure under stress. This is the direct, physical role.
Return Healthy · Research brief
C15:0, the odd-chain fat that protects the membrane you just rebuilt
Pentadecanoic acid was run through BioMAP, a panel of twelve human primary cell systems used by drug developers to profile new compounds. Here is what that work found, what it means for membranes and mitochondria, and where the evidence stops.
What C15:0 is
Pentadecanoic acid is a saturated fatty acid with a fifteen-carbon chain. Almost every fat in the diet has an even number of carbons. C15:0 is one of the few odd-chain fats we eat, and it arrives mainly through whole dairy fat and the fat of ruminant animals, where it is made by rumen bacteria. In dairy fat it accounts for roughly one percent of total fatty acids.
Two things made researchers look at it closely. First, large cohort studies have repeatedly found that people with higher circulating C15:0 have lower rates of cardiometabolic problems over time. Second, population levels of C15:0 have been falling as whole-fat dairy left the diet. In 2020, Venn-Watson and colleagues proposed that C15:0 meets the criteria for an essential fatty acid. That proposal is still debated, and no major nutrition body has adopted it, but it set off the cell-based work this brief describes.
Why saturated matters here. A saturated chain has no double bonds. Double bonds are where free radicals attack a fatty acid, which is why polyunsaturated fats such as EPA and DHA oxidize so easily. C15:0 has none, so once it is built into a membrane phospholipid it holds up under oxidative stress that would degrade the fragile fats around it.
How it was tested
BioMAP Diversity PLUS is a commercial screening platform used in pharmaceutical development. A compound is added to twelve different human primary cell cultures, each stimulated to mimic a type of tissue stress, and 148 protein biomarkers are read across the panel. The pattern that results is compared against a database of thousands of reference compounds, so a new molecule can be read against known drugs.
In 2022, Venn-Watson and Butterworth published a BioMAP profile of C15:0 at four concentrations from 1.9 to 50 µM, run side by side with the omega-3 fatty acid EPA.
12human primary cell systems
148biomarkers read per system
10 of 12systems with dose-dependent C15:0 activity
0systems where C15:0 was cytotoxic, at any dose
The authors count 36 clinically relevant, dose-dependent activities across ten systems. Most were reductions in inflammatory, immune-activation or fibrotic signals; a handful of markers rose. At 17 µM it shared twelve activities with EPA and showed 28 that EPA did not. EPA, at 50 µM, was cytotoxic in four of the twelve systems. C15:0 was not cytotoxic in any system at any concentration tested.
Three mechanisms
The cell work supports three overlapping actions. They are listed in the order they matter for a membrane formula.
Lowers oxidative load
In stressed human liver cells, C15:0 at 10 to 50 µM reduced mitochondrial reactive oxygen species compared with untreated controls. Less ROS means less damage to the inner mitochondrial membrane where energy is made.
Nudges the metabolic switches
C15:0 is a dual partial agonist of PPARα and PPARδ, activates AMPK, and inhibits mTOR, HDAC6 and JAK-STAT signaling. These are the same levers targeted by several longevity and metabolic drugs.
What changed, system by system
The table condenses the published BioMAP results. Each row is one cell system, the biology it models, and the biomarkers that moved significantly with C15:0. A down arrow is a reduction. Markers in the second colour went up. Only effects that held across doses are included.
| System | What it models | Significant changes with C15:0 |
|---|---|---|
| 4H | Th2-type allergic inflammation (endothelium + IL-4, histamine) | ↓ eotaxin-3, ↓ MCP-1, ↓ VEGFR2 |
| LPS | Monocyte–endothelial inflammation via TLR4 (cardiovascular, metabolic) | ↓ CD69, ↓ IL-1α, ↑ thrombomodulin, ↑ tissue factor |
| SAg | T-cell activation (immune, joint, skin, gut) | ↓ CD38, ↓ CD40, ↓ CD69, ↓ T-cell proliferation, ↑ IL-8 |
| BT | B-cell and T-cell co-activation (immune, lung) | ↓ sIgG, ↓ sIL-17F |
| 3C | Vascular inflammation via IL-1β, TNFα, IFNγ (cardiovascular, immune) | ↓ MCP-1, ↓ HLA-DR, ↓ endothelial proliferation |
| HDF3CGF | Fibroblast inflammation and wound response (liver, joint) | ↓ PAI-1, ↓ VCAM-1, ↓ IP-10, ↓ I-TAC, ↓ MIG, ↓ fibroblast proliferation, ↑ TIMP-2 |
| MyoF | Myofibroblast matrix deposition (lung, liver) | ↓ VCAM-1, ↓ collagen I, ↓ IL-8, ↓ decorin, ↓ TIMP-1 |
| BE3C | Bronchial epithelium (lung) | ↓ tPA |
| CASM3C | Coronary artery smooth muscle (cardiovascular, immune) | ↓ IL-6, ↓ VCAM-1, ↓ HLA-DR, ↓ thrombomodulin, ↓ tissue factor, ↓ proliferation |
| Mphg | Macrophage–endothelial inflammation (cardiovascular, joint, immune) | ↓ CD40, ↓ CD69, ↑ MIP-1α, ↑ E-selectin |
Condensed from Figure 3 of Venn-Watson & Butterworth 2022: the activities that changed dose-dependently across 1.9 to 50 µM. Two systems, BF4T (bronchial epithelium with fibroblasts) and KF3CT (keratinocytes with fibroblasts), showed no dose-dependent activity. Several further markers, including TNFα and sIL-17A in the BT system and MCP-1 and CD40 in the LPS system, fell at 17 µM but not across all doses, and are left out.
Recognize any of these?
Several of the biomarkers C15:0 lowered are ones clinicians already track or read about. A short glossary, in physiological terms.
IL-6
The most studied pro-inflammatory cytokine and the upstream signal for CRP. C15:0 lowered it dose-dependently in the coronary artery smooth muscle system. TNFα fell at 17 µM in the B/T-cell system, but not across doses, so we do not count it.
IL-8
The main neutrophil-recruiting chemokine. Lowered in the myofibroblast system, though it rose in the T-cell system, a reminder that these effects are tissue-specific rather than global.
MCP-1 and eotaxin-3
Chemokines that pull monocytes and eosinophils out of the bloodstream and into tissue. They are how a local inflammatory site becomes a persistent one.
VCAM-1
An adhesion molecule on the endothelium. It is the docking site that lets circulating immune cells stick to the vessel wall before crossing into tissue.
PAI-1 and collagen I
Two markers of the fibrotic response. PAI-1 slows clot breakdown and matrix turnover; collagen I is the scaffold that scar tissue is built from.
IL-17F
A cytokine from the Th17 arm of the immune system, associated with autoimmune and barrier-tissue inflammation. Lowered in the B/T-cell system.
Where it acts
The signaling findings come from receptor-binding and enzyme assays in the 2020 paper and from the rapamycin comparison published in 2023. Taken together they describe a molecule that leans metabolism toward repair and fat oxidation and away from growth and inflammatory signaling.
Red blood cells and the liver
The newest line of C15:0 research treats the red blood cell as the index cell. It is almost nothing but membrane, it lives about 120 days, and it is the first cell to fail when membranes are fragile. The argument runs in a chain: fragile red cells die early, the liver's Kupffer cells have to clear them, iron accumulates in the liver, and oxidative stress and fibrosis follow. Strengthen the membrane and the chain breaks at its first link. It is a coherent story and a natural fit for a membrane formula, so it is worth being exact about how much of it is evidence.
In animals
The 2020 Scientific Reports paper reports that C15:0 supplementation attenuated anemia, inflammation, dyslipidemia and fibrosis in animal models, with the liver findings coming from models of fatty liver disease. These are the strongest in vivo data for C15:0 and they are animal data.
In people
One randomized, double-blind, placebo-controlled trial has looked at these markers. Robinson and colleagues gave 200 mg of C15:0 or placebo daily for twelve weeks to thirty young adults with overweight or obesity. Circulating C15:0 rose, and there were no significant adverse events. The authors then split the treated group by how high their blood C15:0 got. In the half who reached a post-treatment level above 5 µg/mL, ALT fell by 29 U/L, AST by 6 U/L, and hemoglobin rose by 0.60 g/dL, compared with treated participants whose levels stayed lower. The authors describe this as "potentially relevant" and "warranting further study."
Read that carefully before repeating it. The hemoglobin and liver-enzyme comparison is between two halves of the treated group, ten people each, not between C15:0 and placebo. It was a secondary analysis in a trial designed to measure blood levels. It is a real signal and a reasonable basis for a larger trial. It is not yet a treatment effect, and clinician-facing materials that say supplementation "resulted in" these changes are ahead of the paper.
In populations
Observational studies associate higher circulating C15:0 with lower liver fat, lower liver enzymes and healthier red cell indices. As with the cardiometabolic associations, these are correlations in people who also eat differently.
Labs the research has used
Red blood cells
Hemoglobin, red cell distribution width (RDW), reticulocyte count. These were the responsive markers in the animal work and the trial.
Iron handling
Ferritin and transferrin saturation. The proposed link between fragile red cells and liver iron runs through these.
Liver
ALT, AST and GGT. ALT and AST moved in the responder half of the trial; GGT was reported separately.
C15:0 itself
A red-blood-cell C15:0 level is sold as an at-home test through Genova Diagnostics. Its deficiency cutoff, about 0.2% of total fatty acids, comes from the same research group's 2024 hypothesis paper, so treat it as a research marker rather than a validated clinical threshold.
None of these labs is a C15:0 claim. They are standard panels, and they are what the published work measured, which makes them the honest place to look if a clinician wants to follow a patient on a membrane protocol.
What the evidence does and does not show
This brief is honest about its evidence because clinicians will ask, and because the cell data are strong enough to stand without inflation.
- Everything above is in vitro. BioMAP is a predictive screen. The authors themselves say the results need in vivo and clinical confirmation.
- Human trials are small. Two twelve-week randomized trials have been published. The Robinson trial above raised circulating C15:0 in thirty young adults with overweight, with the liver and hemoglobin signal confined to a responder subgroup. In women with fatty liver on a Mediterranean diet, adding C15:0 lowered LDL more than diet alone, with similar changes in liver fat. Broad metabolic, cardiovascular or cognitive outcomes have not been demonstrated in people.
- The observational link is association, not cause. Higher blood C15:0 tracks with better cardiometabolic outcomes in cohorts, but C15:0 is also a marker of dairy intake and of other dietary patterns.
- "Essential" is a proposal. It comes from the same research group and has not been adopted by NASEM, EFSA, the AHA or any equivalent body. We use "proposed essential."
- Conflict of interest is real and disclosed. The primary papers are authored by the founder of the company that sells the leading C15:0 supplement, with patents held and partial funding from the U.S. Office of Naval Research. The data are published and peer-reviewed; the framing in press releases often goes further than the papers.
- Safety profile is good. Pure C15:0 holds Generally Recognized as Safe status from the FDA for food use, and the cell panel showed no cytotoxicity at any dose.
Why it is in Phospholipid Synergy
Build the membrane, then protect it
Phospholipid Synergy supplies the membrane phospholipids themselves: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and alpha-GPC. Those fats are rich in polyunsaturated chains, which is what makes a membrane fluid and also what makes it vulnerable to oxidation.
Each scoop now adds 100 mg of C15:0, the standard daily dose used in the leading standalone C15:0 product. The difference is context. Taken alone in a capsule, C15:0 has to find its way into membranes that may be short on the other building blocks. Taken with a full phospholipid complement, it arrives alongside the structures it is meant to stabilize, with mixed tocopherols as a second line against lipid peroxidation.
That is the whole rationale: construction and protection, together. See Phospholipid Synergy →
References
- Venn-Watson S, Butterworth CN. Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: Evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems. PLoS One. 2022;17(5):e0268778. doi:10.1371/journal.pone.0268778
- Venn-Watson S, Lumpkin R, Dennis EA. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential? Sci Rep. 2020;10:8161. doi:10.1038/s41598-020-64960-y
- Venn-Watson S, Schork NJ. Pentadecanoic acid (C15:0), an essential fatty acid, shares clinically relevant cell-based activities with leading longevity-enhancing compounds. Nutrients. 2023;15(21):4607. doi:10.3390/nu15214607
- Robinson MK, Lee E, Ugalde-Nicalo PA, Skonieczny JW, Chun LF, Newton KP, Schwimmer JB. Pentadecanoic acid supplementation in young adults with overweight and obesity: a randomized controlled trial. J Nutr. 2024;154(9):2763-2771. doi:10.1016/j.tjnut.2024.07.030
- Venn-Watson S. The cellular stability hypothesis: evidence of ferroptosis and accelerated aging-associated diseases as newly identified nutritional pentadecanoic acid (C15:0) deficiency syndrome. Metabolites. 2024;14(7):355. doi:10.3390/metabo14070355
- Tylutka A, Walas Ł, Zembron-Lacny A. Level of IL-6, TNF, and IL-1β and age-related diseases: a systematic review and meta-analysis. Front Immunol. 2024;15:1330386. doi:10.3389/fimmu.2024.1330386
- Singh S, Anshita D, Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101:107598. doi:10.1016/j.intimp.2021.107598
- Yamada T, Miyabe Y, Ueki S. Eotaxin-3 as a plasma biomarker for mucosal eosinophil infiltration in chronic rhinosinusitis. Front Immunol. 2019;10:74. doi:10.3389/fimmu.2019.00074
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This brief summarizes published research for educational purposes and is not medical advice.